MedTrace Logo

Study of ATI-450 vs Placebo in Patients With Moderate to Severe Psoriatic Arthritis

NCT05511519 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 47

Last updated 2024-11-27

No results posted yet for this study

Summary

This is a Phase 2a study to investigate the efficacy, safety, tolerability, PK, and PD of ATI-450 versus placebo in patients with moderate to severe psoriatic arthritis.

Conditions

Interventions

DRUG

ATI-450

Oral, small molecule MK2 inhibitor

DRUG

Placebo Oral Tablet

Placebo tablet manufactured to match ATI-450 in appearance

Sponsors & Collaborators

  • Aclaris Therapeutics, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-12
Primary Completion
2023-12-06
Completion
2024-01-03
FDA Drug
Yes

Countries

  • United States
  • Poland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05511519 on ClinicalTrials.gov